Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Dispersible Tablet 30 X 125 mg |
|
37632 | 4832 |
|
Dispersible Tablet 30 X 250 mg |
|
37633 | 4833 |
|
Dispersible Tablet 30 X 500 mg |
|
37634 | 4835 |
Related information
Dosage
For patients > 2 years old:
For patients regularly receiving blood transfusions – 20 mg per kilogram body weight.
For patients who do not regularly receive blood transfusions – 10 mg per kilogram body weight
The maximum daily dosage is:
• 40 mg per kilogram body weight for patients regularly receiving blood transfusions.
• 20 mg per kilogram body weight for adult patients not regularly receiving blood transfusions.
• 10 mg per kilogram body weight for children aged under 18 years not regularly receiving blood transfusions
Please refer to the license holder for further details.
Indications
Treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over). Also indicated for the treatment of chronic iron overload in patients with non–transfusion-dependent thalassemia syndromes aged 10 years and older. Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC]≥5 mg Fe/g dry weight [dw] or serum ferritin consistently >800 μg/l). LIC is the preferred method of iron overload determination and should be used wherever available
Contra-Indications
* Hypersensitivity
* Moderate or severe kidney disease
* Concomitant use of another chelating agent
Special Precautions
Please refer to the license holder for further details.
Side Effects
Please refer to the license holder for further details.
Drug interactions
Please refer to the license holder for further details.
Pregnancy and Lactation
Please refer to the license holder for further details.
Overdose
Please refer to the license holder for further details.